NRx Pharmaceuticals price target raised to $45 from $40 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on NRx Pharmaceuticals (NRXP) to $45 from $40 and keeps a Buy rating on the shares. The firm says the type C FDA meeting “provides a clear” application pathway for NRX-100. This is “supported by real-world evidence and a broader proposed indication, significantly de-risking the program,” the analyst tells investors in a research note. H.C. Wainwright expanded the addressable population for NRX-100 and increased its risk-adjusted NRX-100 valuation to $15 per share from $10.